GLP-1 affordability: $12,700/year pricing raises access concerns

• Marketing practices: Direct-to-consumer advertising scrutiny

 

ESG Ratings: Generally strong scores, but drug pricing remains concern

---

Related Terms

• GLP-1 receptor agonist – Diabetes/obesity drug mimicking GLP-1 hormone
• GIP (Glucose-dependent Insulinotropic Polypeptide) – Hormone regulating insulin and metabolism
• Tirzepatide – Dual GIP/GLP-1 receptor agonist (Mounjaro, Zepbound)
• CDK4/6 inhibitor – Breast cancer drug class (Verzenio)
• Anti-amyloid antibody – Alzheimer’s drug removing brain plaques (donanemab)
• IL-17 inhibitor – Immunology drug class for psoriasis (Taltz)
• JAK inhibitor – Oral immunology drug class (Olumiant)
• Biosimilar – Generic version of biologic drug
• Patent cliff – Revenue loss when drug patents expire
• Blockbuster drug – Drug with $1B+ annual sales

---

Historic Context: Eli Lilly’s Legacy

Pioneering Achievements

Insulin (1923)

• First company to mass-produce insulin
• Partnership with insulin discoverers (Banting, Best)
• Transformed diabetes from fatal to manageable disease
• Foundation of Lilly’s diabetes franchise

Prozac® (1988)

• First selective serotonin reuptake inhibitor (SSRI) antidepressant
• Peak sales: $2.8 billion (2001)
• Revolutionized depression treatment
• Patent expired 2001, generic competition

Zyprexa® (1996)

• Atypical antipsychotic for schizophrenia, bipolar disorder
• Peak sales: $5 billion (2010)
• Patent expired 2011

Cialis® (2003)

• Erectile dysfunction treatment (36-hour duration)
• Peak sales: $2.5 billion (2013)
• Patent expired 2017 (US)

Cymbalta® (2004)

• SNRI antidepressant
• Peak sales: $5 billion (2013)
• Patent expired 2013

The “Lost Decade” (2010-2019)

Patent Cliff Crisis

• 2010-2015: Lost $10B+ annual revenue to patent expiries
• Products lost: Zyprexa, Cymbalta, Prozac, Cialis
• Stock performance: Flat to declining (2010-2016)
• Investor sentiment: Negative, questioned pipeline

Turnaround Strategy (2017-2019)

• New CEO: David Ricks (2017) refocused on innovation
• Pipeline investment: Increased R&D spending
• Strategic acquisitions: Loxo Oncology ($8B, 2019)
• Diabetes focus: Trulicity growth, tirzepatide development

The Renaissance (2020-2024)

GLP-1 Revolution

• 2022: Mounjaro FDA approval (May)
• 2023: Zepbound FDA approval (November)
• Stock performance: +500% (2019-2024)
• Market cap: $120B (2019) → $750B (2024)
• Transformation: From struggling pharma to growth leader

---

The Obesity Market Revolution

Why GLP-1 Drugs Are Game-Changing

Historical Context

• Previous obesity drugs: Modest weight loss (5-10%), safety issues, withdrawn from market
• Bariatric surgery: Effective (25-30% weight loss) but invasive, risky, expensive
• Diet/exercise: <5% long-term success rate
• Unmet need: No effective, safe, convenient obesity treatment

GLP-1 Breakthrough

• Efficacy: 15-25% weight loss (comparable to bariatric surgery)
• Safety: Generally well-tolerated (GI side effects manageable)
• Convenience: Weekly injection (vs daily pills, surgery)
• Metabolic benefits: Improved blood sugar, blood pressure, lipids, liver fat
• Cardiovascular benefits: Reduced heart attack, stroke risk

Societal Impact

• Obesity epidemic: 42% of US adults obese (2020)
• Healthcare costs: $173 billion annually (US obesity-related costs)
• Comorbidities: Diabetes, heart disease, cancer, sleep apnea, arthritis
• Potential: GLP-1 drugs could reduce obesity-related disease burden

Cultural Phenomenon

• Celebrity endorsements: Oprah Winfrey, Elon Musk publicly discussing GLP-1 use
• Social media: #Ozempic trending, viral weight loss stories
• Mainstream awareness: GLP-1 drugs household names
• Demand surge: Shortages, compounding pharmacies, black market

---

Investment Considerations: Risk vs. Reward

For Growth Investors

Pros

• ✅ Explosive growth: 30%+ revenue growth (2024-2028)
• ✅ Market leadership: Winning GLP-1 race vs Novo Nordisk
• ✅ Pipeline depth: Next-generation drugs (orforglipron, retatrutide)
• ✅ Multiple catalysts: Label expansions, new indications, Alzheimer’s
• ✅ Long runway: <1% market penetration, decades of growth

Cons

• ❌ Valuation risk: 55x P/E, high expectations priced in
• ❌ Competition: Novo Nordisk, Amgen, others developing GLP-1s
• ❌ Execution risk: Manufacturing, clinical trials, regulatory
• ❌ Volatility: Stock swings 10-20% on news

For Value Investors

Pros

• ✅ Earnings growth: 20%+ EPS growth justifies valuation
• ✅ Cash flow: Strong free cash flow generation
• ✅ Competitive moat: Technology, manufacturing, patents

Cons

• ❌ No margin of safety: Trading at all-time highs
• ❌ Expensive vs peers: 3x P/E of Merck, J&J
• ❌ Limited downside protection: High valuation = high risk

For Dividend Investors

Pros

• ✅ Dividend growth: 15%+ annual increases
• ✅ Sustainable payout: 40% payout ratio
• ✅ Long history: 140+ years of dividends

Cons

• ❌ Low yield: 0.6-0.7% (vs 3-6% for other pharma)
• ❌ Better options: Pfizer (6.5%), AbbVie (3.5%), Merck (2.8%)

For Conservative Investors

Pros

• ✅ Defensive sector: Healthcare spending non-discretionary
• ✅ Strong balance sheet: Investment-grade credit rating
• ✅ Diversified portfolio: Diabetes, oncology, immunology, neuroscience

Cons

• ❌ High volatility: Stock swings more than market
• ❌ Concentration risk: 50%+ revenue from GLP-1 drugs (2024)
• ❌ Regulatory risk: Drug pricing, safety concerns

---

Conclusion: A Historic Opportunity or Overvalued?

The Bull Perspective

Eli Lilly is experiencing a once-in-a-generation transformation driven by revolutionary GLP-1 drugs that are solving the obesity epidemic. With 20%+ EPS growth for the next 5+ years, a deep pipeline, and massive market opportunity, the premium valuation is justified. This is the pharmaceutical equivalent of investing in Apple during the iPhone era.

The Bear Perspective

Eli Lilly is trading at nosebleed valuations (55x P/E) with all good news priced in. Competition is intensifying, reimbursement is uncertain, and safety concerns loom. The stock has run too far, too fast, and any disappointment will cause a sharp correction. Better opportunities exist in cheaper pharma stocks.

The Balanced View

Eli Lilly is a high-quality company with genuine growth drivers, but valuation matters. The stock is expensive by any measure, offering limited margin of safety. For long-term investors willing to accept volatility and high valuation risk, Lilly offers exposure to the obesity mega-trend. For conservative investors, waiting for a pullback (20-30%) would provide better entry point. Dollar-cost averaging may be prudent strategy given volatility.

---

Disclaimer: This information is for educational purposes only and does not constitute financial or medical advice. Eli Lilly stock carries risks including high valuation, GLP-1 competition, reimbursement uncertainty, safety concerns, patent cliffs, clinical trial failures, regulatory changes, and execution challenges. DYOR before making investment decisions. Past performance is not indicative of future results. Consult with financial advisors regarding investment decisions and healthcare professionals regarding medical products.

---

Official Website: www.lilly.com

Investor Relations: investor.lilly.com

NYSE Listing: www.nyse.com (Code: LLY)

SEC Filings: www.sec.gov (Search: Eli Lilly and Company)

Related Topics: Eli Lilly, NYSE:LLY, GLP-1 Drugs, Mounjaro, Zepbound, Tirzepatide, Obesity Drugs, Weight Loss Medications, Diabetes Drugs, Verzenio, Breast Cancer, Donanemab, Kisunla, Alzheimer’s Disease, Taltz, Immunology, Growth Stocks, Pharmaceutical Stocks, Healthcare Stocks, Novo Nordisk Competition, Ozempic Alternative, Drug Pricing, Blockbuster Drugs